Neuronal Potassium Channel Openers Flupirtine (SNEPCO) in the Treatment of the Pharmacoresistant Epilepsy

Abstract

Introduction

Flupirtine is used in many European countries for the treatment of different pain states because of its analgesic attributes. It is a centrally acting, non-opioid analgesic.

Objective

The aim of the study was to investigate an entire study the possibility of applying flupirtine (ktadolona) – selective neuronal potassium channel activators in the treatment of pharmacoresistant epilepsy and related non-psychotic depressive disorder in adults.

Material and methods

A total of 20 patients with the diagnosis of primary – generalized idiopathic epilepsy (IGE) and “non-psychotic depressive disorder due to epilepsy (F06.362)”. Before applying katadolon forte, patients received standard antiepileptic and antidepressant drugs (Depakine-Chrono 1000 mg/day, 150 mg lamotrigine/day, levitiratsetam 3000 mg/day of citalopram 20 mg/day). Assigning a first katadolon fote 14 days 200 mg 2 times a day, followed by 200 mg three in day inside.

Results

Of the 20 patients, 10 had no seizures, 8 marked decrease in the frequency of seizures in 2 patients therapy was not effective.

Conclusion

Our data should be considered preliminary, because small sample of patients and duration of follow-up (18 months). The next phase of work will be carried out on a large sample of patients and a longer observation, placebo – controlled, double blind study.

Disclosure of interest

The authors have not supplied their declaration of competing interest.